{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:14:39Z","timestamp":1760955279636},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T00:00:00Z","timestamp":1303689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:p>Saueressig MG, Boussaud V, Amrein C, Guillemain R, Souilamas J, Souilamas R. Risk factors for post\u2010transplant lymphoproliferative disease in patients with cystic fibrosis.\u2028Clin Transplant 2011: 25: E430\u2013E436. \u00a9 2011 John Wiley &amp; Sons A\/S.<\/jats:p><jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The objective of this study was to retrospectively analyze risk factors associated with post\u2010transplant lymphoproliferative disease (PTLD) in a cohort of 112 lung transplant recipients with cystic fibrosis (CF). Prior to transplantation, patients were tested for Epstein\u2013Barr virus (EBV), human herpesvirus (HHV types 1, 2, 3, 6, and 8), herpes zoster virus, and cytomegalovirus (CMV) serologies. PTLD diagnosis was established based on increased EBV viral charge plus clinical\/radiographic findings and confirmed by biopsy. Negative EBV and HHV serologies at the time of lung transplantation (LTx) were significant risk factors associated with development of PTLD in patients with CF in the univariate logistic regression analysis (p\u2003&lt;\u20030.05) and also in the multivariate analysis (odds ratio of 77.5 and 12.5, respectively). CMV serology, CMV mismatch, acute rejection in the first three\u2003months following LTx, HLA\u2010A3 antigen expression, and female gender did not affect PTLD. Our study confirmed the presence of a strong association between negative EBV serology at the time of LTx and PTLD and suggested an independent effect of negative HHV serology on PTLD.<\/jats:p>","DOI":"10.1111\/j.1399-0012.2011.01464.x","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T02:35:39Z","timestamp":1303785339000},"source":"Crossref","is-referenced-by-count":17,"title":["Risk factors for post\u2010transplant lymphoproliferative disease in patients with cystic fibrosis"],"prefix":"10.1111","volume":"25","author":[{"given":"Maur\u00edcio G.","family":"Saueressig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Boussaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Amrein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Guillemain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihane","family":"Souilamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redha","family":"Souilamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.08.004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.9901013"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.6.8970360"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802311417"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.76"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200112150-00012"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199312000-00023"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.089458"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(95)70064-1"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(90)90058-N"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(00)00149-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03240-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-165"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(99)00060-8"},{"key":"e_1_2_6_16_2","first-page":"78","article-title":"Evaluation of four commercially available Epstein\u2013Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method","volume":"10","author":"Gartner BC","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-077982"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505043321802"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301241"},{"key":"e_1_2_6_20_2","first-page":"501","article-title":"Human herpesvirus\u20106 (HHV\u20106) in Hodgkin\u2019s disease: cellular expression of viral antigens as compared to oncogenes met and fes tumor suppressor gene product p53, and interleukins 2 and 6","volume":"8","author":"Krueger GR","year":"1994","journal-title":"In Vivo"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq043"},{"key":"e_1_2_6_22_2","first-page":"1106","article-title":"Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?","volume":"23","author":"Cockfield SM","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.13.3.7544594"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70116-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200804-531OC"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00253.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(02)03511-X"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200008270-00010"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199812270-00006"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-0012.2011.01464.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-0012.2011.01464.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:25:39Z","timestamp":1697376339000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-0012.2011.01464.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,25]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1399-0012.2011.01464.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-0012.2011.01464.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,25]]}}}